Conolidine’s analgesic outcomes stem from its conversation with non-opioid pain pathways. Unlike opioids, which bind to µ-opioid receptors within the central anxious system, conolidine modulates alternate molecular targets. A Science Improvements research discovered that conolidine interacts Along with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availab... https://johnm431sbi8.wikikarts.com/user